Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

Journal of Virology

Volumn 75, Issue 16, 2001, Pages 7290-7304

  Guirakhoo, F ^a   Arroyo, J ^a   Pugachev, K V ^a   Miller, C ^a   Zhang, Z X ^a   Weltzin, R ^a   Georgakopoulos, K ^a   Catalan, J ^a   Ocran, S ^a   Soike, K ^b   Ratterree, M ^b   Monath, T P ^a  

^a Acambis   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHESUS MONKEY; SEROCONVERSION; VERO CELL; VIREMIA; VIRUS ENVELOPE; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

ANIMALS; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VIRUS; MICE; REASSORTANT VIRUSES; VERO CELLS; VIRAL VACCINES; YELLOW FEVER VIRUS;

EID: 0034897886     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.16.7290-7304.2001     Document Type: Article

References (58)

1. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E
2. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3
3. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses
4. Vaccine development against dengue and Japanese encephalitis: Report of a World Health Organization meeting
5. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties
6. Genetic relatedness among structural protein genes of dengue 1 virus strains
7. Identification of an epitope on the DEN virus membrane (M) protein defined by cross-protective Mabs: Design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins
8. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines
9. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA
10. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
11. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis
12. Human behavior and cultural context in disease control
13. Dengue epidemic in southern Vietnam, 1998
14. Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion
15. Pathogenesis of dengue: Challenge to molecular biology
16. Antibody, macrophage, dengue virus infection, shock and hemorrhage: A pathogenic cascade
17. Original antigenic sin in dengue
18. Immunologic studies with yellow fever and selected African group B arboviruses in rhesus and vervet monkeys
19. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis
20. Chimeric DEN type 2 (vaccine strain PDK-53)/DEN type 1 virus as a potential candidate DEN type 1 virus vaccine
21. Characterization of Langat virus antigenic determinants defined by Mabs to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibody
22. Original antigenic sin" phenomenon in experimental flavivirus infections of guinea pigs: Studies by enzyme-linked immunosorbent assay
23. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-non-immune and vaccinia-immune humans
24. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers
25. Mabs for DEN virus prM glycoprotein protect mice against lethal DEN infection
26. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever
27. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine
28. Induction of protective immunity against Japanese encephalitis with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes
29. Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections
30. Dengue virus structural differences that correlate with pathogenesis
31. Human dendritic cells are activated by dengue virus infection: Enhancement by gamma interferon and implications for disease pathogenesis
32. The nucleotide sequence of dengue type 4 virus: Analysis of genes coding for nonstructural proteins
33. Studies on serological crossreaction in sequential flavivirus infections
34. Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors
35. Dengue viral infections; pathogenesis and epidemiology
36. Dengue - The risk to developed and developing countries
37. Yellow fever
38. Chimeric yellow fever 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys
39. Recombinant, chimeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) and the capsid and nonstructural genes of yellow fever (17D) is safe, immunogenic and protective in non-human primates
40. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever
41. Complete nucleotide sequence of dengue type 3 virus genome RNA
42. Transcription of infectious yellow fever virus RNA from full-length cDNA templates produced by in vitro ligation
43. Molecular evolution of dengue type 2 virus in Thailand
44. Dengue and dengue haemorrhagic fever
45. Experimental studies of New World monkeys with dengue and yellow fever
46. Comments on the epidemiology, pathogenesis and control of dengue
47. Serotypes and genotypes of DEN virus circulating in Venezuela, 1990-1997
48. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses
49. Replication of yellow fever virus in the mouse central nervous system: Comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain
50. Dengue-2 vaccine: Dose response in volunteers in relation to yellow fever immune status
51. Experimental studies of dengue
52. Immunological studies with group B arthropod-borne viruses. II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subject following administration of 17D yellow fever vaccine
53. The relative resistance of dengue-immune monkeys to yellow fever virus
54. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: Quantitation of the dengue virus-specific CD8 T-cell response
55. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity
56. Sequential dengue virus infections in the white-handed gibbon (Hylobates lar)
57. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus